Sanofi CFO Jean-Baptiste de Chatillon (L) and CEO Paul Hudson (Romuald Meigneux/Sipa via AP Images)

Three­'s com­pa­ny: Sanofi fol­lows lead of Lil­ly and No­vo, slash­es in­sulin price by 78% and caps out-of-pock­et costs

Sanofi to­day joined with the oth­er two in­sulin jug­ger­nauts in the US to low­er the price of its best-sell­ing in­sulin prod­uct, Lan­tus (in­sulin glargine), by 78% and set a $35 cap on out-of-pock­et costs for Lan­tus for all pa­tients with com­mer­cial in­sur­ance. The price shifts will be­gin in Jan­u­ary 2024.

The shift from Sanofi fol­lows No­vo Nordisk’s up to 75% price cuts for its in­sulins, be­gin­ning in 2024, and Eli Lil­ly’s sim­i­lar 70% dis­count on its pop­u­lar Hu­ma­log in­sulin prod­uct, which will oc­cur in the fourth quar­ter of this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.